Reconstituted HDL Formulation Reducing Detergent-Induced Liver Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Reconstituted high-density lipoprotein (HDL) formulations used for treating cardiovascular diseases often exhibit liver toxicity due to high levels of detergents, which limits their therapeutic efficacy and safety.
Innovation Solution
A reconstituted HDL formulation with reduced detergent levels, specifically between 5-50% of the concentration that causes liver toxicity, combined with optimal apolipoprotein and phospholipid ratios, to minimize liver toxicity while maintaining therapeutic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high levels of detergent are used in reconstituted HDL formulation, then the formulation can be produced and maintained, but liver toxicity occurs
Solution Approach 1:
The patent applies parameter changes by reducing the detergent concentration from traditional high levels to specifically 0.01-0.1% (w/v), which is a 100-1000 fold reduction. This parameter modification allows the formulation to maintain stability while eliminating liver toxicity, as demonstrated in the clinical trial where the reduced detergent level prevented hepatotoxicity compared to conventional formulations
Solution Approach 2:
The patent converts the harmful effect of detergent-induced liver toxicity into a benefit by carefully controlling detergent levels to be so low that they become harmless while still serving their functional purpose. The detergent is reduced to a level where it no longer causes toxicity but maintains necessary formulation properties, effectively turning a harmful factor into a benign or beneficial component
2Productivity
If high doses of reconstituted HDL formulation are administered, then therapeutic efficacy is improved, but liver toxicity increases
Solution Approach 1:
The patent changes the critical parameter of detergent concentration to a safe level (0.01-0.1%), which allows for high dose administration (up to 100 mg/kg body weight) without proportionally increasing liver toxicity. This parameter change decouples the relationship between dose and toxicity, enabling effective treatment at high doses while maintaining safety
3Ease of manufacture
If traditional detergent levels are used, then formulation can be produced, but safety is compromised
Solution Approach 1:
The patent modifies the detergent concentration parameter to an extremely low level (0.01-0.1%), which surprisingly maintains formulation production feasibility while dramatically improving the safety profile. The formulation can still be manufactured with proper lipid-to-protein ratios and maintains therapeutic activity despite the reduced detergent content
Data Source
AI summary
A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.